|
Age (mean ± SD)
|
49.4 ± 16.0
|
41.1 ± 5.7
|
61.3 ± 14.3
|
43.1 ± 16.5
|
|
Disease duration (mean ± SD)
|
15.6 ± 8.2
|
13.7 ± 6.7
|
21.7 ± 8.5
|
10.8 ± 4.5
|
|
Gender, female, n
|
26
|
9
|
10
|
7
|
|
Cumulative 1997 ACR criteria
|
|
Malar rash
|
12 (46.2)
|
5 (55.5)
|
4 (40.0)
|
3 (42.8)
|
|
Discoid rash
|
2 (7.7)
|
0
|
1 (10.0)
|
1 (14.3)
|
|
Photosensitivity
|
4 (15.4)
|
1 (11.1)
|
2 (20.0)
|
1 (14.3)
|
|
Oral/nasopharyngeal ulcers
|
2 (7.7)
|
0
|
1 (10.0)
|
1 (14.3)
|
|
Serositis
|
15 (57.7)
|
4 (44.4)
|
8 (80.0)
|
3 (42.8)
|
|
Renal disorders
|
5 (19.2)
|
0
|
2 (20.0)
|
3 (42.8)
|
|
Neurologic disorders
|
2 (7.7)
|
0
|
2 (20.0)
|
0
|
|
Hematological disorders
|
14 (53.8)
|
5 (55.5)
|
7 (70.0)
|
2 (28.6)
|
|
ANA
|
26 (100)
|
9 (100)
|
10 (100)
|
7 (100)
|
|
Anti-dsDNA
|
18 (69.2)
|
6 (66.7)
|
8 (80.0)
|
4 (57.1)
|
|
Antiphospholipid antibodies
|
7 (26.9)
|
3 (33.3)
|
3 (30.0)
|
1 (14.3)
|
|
Other laboratory findings
|
|
Anti-Ro/SSA
|
14 (53.8)
|
4 (44.4)
|
5 (50.0)
|
5 (71.4)
|
|
Anti-La/SSB
|
2 (7.7)
|
0
|
1 (10.0)
|
1 (14.3)
|
|
Anti-RNP
|
2 (7.7)
|
0
|
0
|
2 (28.6)
|
|
Anti-Sm
|
2 (7.7)
|
0
|
0
|
2 (28.6)
|
|
Rheumatoid factor
|
11 (37.9)
|
7 (77.8)
|
1 (10.0)
|
3 (42.8)
|
|
Anti-CCP
|
7 (26.9)
|
6 (66.7)
|
0
|
1 (14.3)
|
|
SLICC/damage index (mean ± SD)
|
1.4 ± 1.3
|
1.4 ± 0.5
|
2.6 ± 1.3
|
0.6 ± 0.5
|
|
Medication receiveda
|
|
Total corticosteroid dose >50 g
|
15 (57.7)
|
3 (33.3)
|
10 (100)
|
2 (28.6)
|
|
Antimalarial agents
|
25 (96.1)
|
8 (88.9)
|
10 (100)
|
7 (100)
|
|
Methotrexate
|
20 (76.9)
|
9 (100)
|
6 (60.0)
|
5 (71.4)
|
|
Azathioptine
|
7 (26.9)
|
1 (11.1)
|
4 (40.0)
|
2 (28.6)
|
|
Micophenolate
|
4 (15.4)
|
1 (11.1)
|
1 (10.0)
|
2 (28.6)
|
|
Rituximab
|
8 (30.7)
|
4 (44.4)
|
2 (20.0)
|
2 (28.6)
|
|
Belimumab
|
1 (3.8)
|
0
|
0
|
1 (14.3)
|
|
Anti TNF-alpha
|
3 (11.5)
|
3(33.3)
|
0
|
0
|
|
Anti IL-6
|
2 (7.7)
|
1 (11.1)
|
1 (10.0)
|
0
|
